Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Cited by 19 Publications

Science, 2017, eaal3755

PubMed: 28302793

Sci Transl Med, 2018, 10(433)

PubMed: 29563317

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed:

Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed:

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371
BMC Cancer, 2012, 12:541

PubMed: 23171055

RSC Adv, 2011, 1:884-892

PubMed:

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318

J Nanopart Res, 2014, 16:2340

PubMed:

5 Customer Reviews

(F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.
Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.
Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	NXPtfJdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDBTWM2OD1yLkCwNFI5PyEQvF2=	NH\CdW9USU6JRWK=
LC-2-ad	M3fie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMECwN\|E4KM7:TR?=	M1m2e3NCVkeHUh?=
RL95-2	NFvwc\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInKSJZKSzVyPUCuNFAxPjZ6IN88US=>	NFG1OlJUSU6JRWK=
MZ1-PC	M1Gxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMECwO\|I6KM7:TR?=	M{fINXNCVkeHUh?=
TE-8	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTBwMECxNVch\|ryP	M2rWcXNCVkeHUh?=
SW954	NV7hR4dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\CdGJ2UUN3ME2wMlAxOTF7IN88US=>	MXPTRW5ITVJ?
TE-11	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjoeVJKSzVyPUCuNFAyOjNizszN	NUjRd\|FGW0GQR1XS
PSN1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fsNGlEPTB;MD6wNFE{KM7:TR?=	MmfrV2FPT0WU
MOLT-4	MmLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3CTWM2OD1yLkCwNVQ6KM7:TR?=	NIO5XmVUSU6JRWK=
697	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXCb2djUUN3ME2wMlAxOTVizszN	MmrBV2FPT0WU
ETK-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi0WZpKSzVyPUCuNFAyPTJizszN	NEf1PIhUSU6JRWK=
TE-10	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4[zdWlEPTB;MD6wNFE2PCEQvF2=	NV;HdJJzW0GQR1XS
HUTU-80	M1Pn[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnxOFd5UUN3ME2wMlAxOTZ6IN88US=>	NFrhTmxUSU6JRWK=
NTERA-S-cl-D1	M{m3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XFVmlEPTB;MD6wNFIxQSEQvF2=	MoDVV2FPT0WU
MFH-ino	Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwMECyOlgh\|ryP	NW\tUGNrW0GQR1XS
IA-LM	M{fSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrkTJlKSzVyPUCuNFAzQCEQvF2=	MXTTRW5ITVJ?
MC116	NUjscIloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\YfpFKSzVyPUCuNFAzQDlizszN	M4LVXHNCVkeHUh?=
RKO	M{XEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMECyPVgh\|ryP	NYHtUmY1W0GQR1XS
MRK-nu-1	M2Xvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHsTWM2OD1yLkCwNlk6KM7:TR?=	MoDQV2FPT0WU
VA-ES-BJ	NUnjfZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzGTWM2OD1yLkCwN{DPxE1?	NYD5[Zh1W0GQR1XS
KALS-1	NFfR[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMECzNFgh\|ryP	MYDTRW5ITVJ?
BB30-HNC	NUfMO5BHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TjcGlEPTB;MD6wNFMyPCEQvF2=	MojlV2FPT0WU
ACN	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXLZ2JIUUN3ME2wMlAxOzF4IN88US=>	MXPTRW5ITVJ?
TE-9	NGr3cHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMECzNlYh\|ryP	M3H5dHNCVkeHUh?=
SIG-M5	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMECzNlch\|ryP	NYTsOpRbW0GQR1XS
no-10	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMECzOlIh\|ryP	M1jxSHNCVkeHUh?=
EW-1	M33PSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fQSWlEPTB;MD6wNFM4OSEQvF2=	NGTBR2VUSU6JRWK=
SK-LMS-1	M4LyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1m1XGlEPTB;MD6wNFQxOSEQvF2=	NVvifY9KW0GQR1XS
GT3TKB	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnweYxKSzVyPUCuNFA1OzRizszN	MX\TRW5ITVJ?
ES4	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnWOWNPUUN3ME2wMlAxPDR7IN88US=>	MXnTRW5ITVJ?
IMR-5	NIXEU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMEC0OUDPxE1?	M17VZnNCVkeHUh?=
NCI-H1648	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMEC0Olkh\|ryP	MmT6V2FPT0WU
MV-4-11	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHBNpVKSzVyPUCuNFA1PzVizszN	NIm2fWxUSU6JRWK=
SK-UT-1	M1rofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3YNGJKSzVyPUCuNFA1QCEQvF2=	MWXTRW5ITVJ?
NB13	NX\CSINWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33oZWlEPTB;MD6wNFQ6OSEQvF2=	NI[1Tm9USU6JRWK=
DJM-1	NFnWSJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTXN\|hSUUN3ME2wMlAxPTNizszN	MkPjV2FPT0WU
ES8	M17HSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fzUmlEPTB;MD6wNFU{QCEQvF2=	NIPtSXpUSU6JRWK=
TE-6	NH;IcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zFbmlEPTB;MD6wNFU4KM7:TR?=	NVHCWIJjW0GQR1XS
KS-1	NV7nclBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4T0N2lEPTB;MD6wNFU5OiEQvF2=	M4D3NXNCVkeHUh?=
TE-1	NWrNXYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\6TWM2OD1yLkCwOlA3KM7:TR?=	NV3oSmNJW0GQR1XS
ATN-1	M3v6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nwVmlEPTB;MD6wNFYxQSEQvF2=	M4TwSXNCVkeHUh?=
A4-Fuk	NGXs[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHGSZlIUUN3ME2wMlAxPjFzIN88US=>	NELzSGVUSU6JRWK=
ALL-PO	NXzVfHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7RflFTUUN3ME2wMlAxPjNizszN	NUjVcWNFW0GQR1XS
BE-13	M4nzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;NZmlEPTB;MD6wNFY{PiEQvF2=	MkDDV2FPT0WU
KM12	NYDY[mpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\n[ll2UUN3ME2wMlAxPjN5IN88US=>	M3u4cHNCVkeHUh?=
NOS-1	M3PNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\qNWlEPTB;MD6wNFY2KM7:TR?=	NYLUbo9RW0GQR1XS
SW962	NXrvSmhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF70cHZKSzVyPUCuNFA3PjJizszN	M1\FXnNCVkeHUh?=
OCUB-M	NYC0TFhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jx[2lEPTB;MD6wNFY3OiEQvF2=	NHL1eZNUSU6JRWK=
NCI-H510A	Mn[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMEC2OlUh\|ryP	Mn3kV2FPT0WU
EW-16	NV7MUItNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPkTWM2OD1yLkCwOlk1KM7:TR?=	M33iVnNCVkeHUh?=
KGN	NWXW[ZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3iTWM2OD1yLkCwO\|EzKM7:TR?=	M{\GPHNCVkeHUh?=
LS-411N	NV3mNmpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjVOphKSzVyPUCuNFA4OTdizszN	M4HZR3NCVkeHUh?=
Becker	NWr4RXN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\vTWM2OD1yLkCwO\|Ih\|ryP	M1rpN3NCVkeHUh?=
HC-1	NEXXOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Pmb2lEPTB;MD6wNFczOSEQvF2=	NF\G[3hUSU6JRWK=
CESS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVviV5Q6UUN3ME2wMlAxPzN5IN88US=>	NYDNfHBCW0GQR1XS
KURAMOCHI	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWO5XXhVUUN3ME2wMlAxPzR6IN88US=>	NFzuc3VUSU6JRWK=
TGBC24TKB	M2jCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYSzUYNkUUN3ME2wMlAxPzV{IN88US=>	NWXZ[21wW0GQR1XS
SW982	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;sS2lEPTB;MD6wNFc3PiEQvF2=	NIf2TmhUSU6JRWK=
HCE-4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnNOpEzUUN3ME2wMlAxPzZ5IN88US=>	MmH6V2FPT0WU
LOUCY	NE\USlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1WxSWlEPTB;MD6wNFc4PSEQvF2=	M2PJRnNCVkeHUh?=
8-MG-BA	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX35W417UUN3ME2wMlAxPzl4IN88US=>	M1rDPXNCVkeHUh?=
HT-144	M17xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M336OGlEPTB;MD6wNFgh\|ryP	NV;6NZUzW0GQR1XS
LXF-289	NWPFTlZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW[1SFRHUUN3ME2wMlAxQDF6IN88US=>	NI\DU3VUSU6JRWK=
RS4-11	MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfYTWM2OD1yLkCwPFM3KM7:TR?=	NWfWNm9qW0GQR1XS
DEL	NH;1[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLaUVFKSzVyPUCuNFA5PDVizszN	Mn\nV2FPT0WU
OCI-AML2	NGOyO2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\KfmlEPTB;MD6wNFg2OiEQvF2=	MoXPV2FPT0WU
CCRF-CEM	M1i0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fsUmlEPTB;MD6wNFg4OSEQvF2=	MV\TRW5ITVJ?
A388	M2HqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfn[Jk2UUN3ME2wMlAxQDd2IN88US=>	MlL5V2FPT0WU
KNS-42	M1O0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3jTWM2OD1yLkCwPFkyKM7:TR?=	NFXUb2RUSU6JRWK=
OVCAR-4	M3rGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHFTWM2OD1yLkCwPVA1KM7:TR?=	NG\Lb2ZUSU6JRWK=
NCI-H1355	NHq2Z\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMEC5NVQh\|ryP	MkXZV2FPT0WU
BL-70	NHzhb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrlbFJKSzVyPUCuNFA6OyEQvF2=	MV\TRW5ITVJ?
BL-41	NGnv[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\UfFlvUUN3ME2wMlAxQTN2IN88US=>	M2rTOXNCVkeHUh?=
A101D	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWP0fIFUUUN3ME2wMlAxQTZizszN	M4PYenNCVkeHUh?=
HL-60	NWPTU4N2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzGeXpKSzVyPUCuNFA6PjZizszN	NFzT[nRUSU6JRWK=
COR-L279	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjaOIZxUUN3ME2wMlAxQTl7IN88US=>	M2LzbXNCVkeHUh?=
NCI-SNU-16	NVn2R5NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX[1PYtHUUN3ME2wMlAyODB6IN88US=>	MlfSV2FPT0WU
Calu-6	M1jDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLPTWM2OD1yLkCxNFEzKM7:TR?=	NHn1b2xUSU6JRWK=
SR	NUHwbIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn74TWM2OD1yLkCxNFI3KM7:TR?=	NVz2c45FW0GQR1XS
QIMR-WIL	NHzCPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TUXGlEPTB;MD6wNVA{OyEQvF2=	MYnTRW5ITVJ?
LB647-SCLC	M17BV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\YPFZKSzVyPUCuNFExPTFizszN	M1y5WnNCVkeHUh?=
RPMI-8226	M{P1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PtR2lEPTB;MD6wNVExOiEQvF2=	MX\TRW5ITVJ?
SK-PN-DW	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TvR2lEPTB;MD6wNVEyOiEQvF2=	M2nxTHNCVkeHUh?=
SF268	M4PLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjKUG9KSzVyPUCuNFEyPTFizszN	M1\xO3NCVkeHUh?=
HD-MY-Z	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fzTmlEPTB;MD6wNVE3OyEQvF2=	MXPTRW5ITVJ?
DOHH-2	NVi1fVlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nCeWlEPTB;MD6wNVIxOyEQvF2=	NHHJ[3VUSU6JRWK=
SCC-3	MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2q1fGlEPTB;MD6wNVIxPCEQvF2=	MXvTRW5ITVJ?
ST486	MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGOwTIFKSzVyPUCuNFEzODRizszN	MkDlV2FPT0WU
NALM-6	NVu3blRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVv2XIt{UUN3ME2wMlAyOjF2IN88US=>	MY\TRW5ITVJ?
NCI-H1436	NV\adIxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfkO41RUUN3ME2wMlAyOjNzIN88US=>	M2PnfnNCVkeHUh?=
KE-37	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrpTWM2OD1yLkCxNlM1KM7:TR?=	MXrTRW5ITVJ?
RPMI-8402	MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHCdmF{UUN3ME2wMlAyOjV4IN88US=>	NVrBcGJ{W0GQR1XS
RXF393	NHz5[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4OxNWlEPTB;MD6wNVI2PyEQvF2=	NYHWV4VNW0GQR1XS
KARPAS-45	MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1[ye2lEPTB;MD6wNVI4KM7:TR?=	NXvLWopIW0GQR1XS
HOP-62	NEXYV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlOwTWM2OD1yLkCxNlc3KM7:TR?=	M{jx[nNCVkeHUh?=
ES1	NH7L[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1T4PWlEPTB;MD6wNVI5QCEQvF2=	MnjkV2FPT0WU
L-363	NEHvV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX4V3JKSzVyPUCuNFE{PTFizszN	NGnVPGVUSU6JRWK=
GI-1	MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7XUXpuUUN3ME2wMlAyOzd\|IN88US=>	MkS3V2FPT0WU
CTV-1	M1zFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUWwV\|BIUUN3ME2wMlAyPDd6IN88US=>	NGjQWFBUSU6JRWK=
TE-5	NFW1OmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrZR\|RKSzVyPUCuNFE1QTZizszN	NFn1OndUSU6JRWK=
SNU-C2B	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rBdmlEPTB;MD6wNVQ6PiEQvF2=	M1nSNXNCVkeHUh?=
K-562	NHXUeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH76OnBKSzVyPUCuNFE2OTZizszN	M1HnOXNCVkeHUh?=
SNB75	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonyTWM2OD1yLkCxOVQh\|ryP	NVfWb3lSW0GQR1XS
MOLT-13	NGjGc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXwTWM2OD1yLkCxOlM4KM7:TR?=	NXOwOlU3W0GQR1XS
LS-123	NXLVeHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zm[WlEPTB;MD6wNVY3PCEQvF2=	M4DxSHNCVkeHUh?=
NCI-SNU-5	NXK0WmVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTZTWM2OD1yLkCxO\|AyKM7:TR?=	M3fKZnNCVkeHUh?=
Daudi	NEnaOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3oVm1IUUN3ME2wMlAyPzB6IN88US=>	M2XVNnNCVkeHUh?=
A253	NWLaUWJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvnT2hEUUN3ME2wMlAyPzN6IN88US=>	NFjMWo1USU6JRWK=
TGBC1TKB	NYO4eIJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTuT\|U3UUN3ME2wMlAyPzV{IN88US=>	MV;TRW5ITVJ?
SJSA-1	NX30UoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;ETWM2OD1yLkCxO\|Y4KM7:TR?=	MmniV2FPT0WU
NCCIT	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXJNoRKSzVyPUCuNFE4PjlizszN	NX3WVpdtW0GQR1XS
NCI-H69	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEG3O\|gh\|ryP	NGXvPWNUSU6JRWK=
SH-4	NVrQflhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIS5UGpKSzVyPUCuNFE5QTVizszN	MlnXV2FPT0WU
HCC1187	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3sTWM2OD1yLkCxPVI1KM7:TR?=	NEn3flhUSU6JRWK=
HCC1599	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXtWnNKSzVyPUCuNFIxOiEQvF2=	MUTTRW5ITVJ?
ONS-76	MkTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILWV5BKSzVyPUCuNFIxOzZizszN	M{TEcHNCVkeHUh?=
KU812	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nUN2lEPTB;MD6wNlA{QSEQvF2=	MV\TRW5ITVJ?
ML-2	NX31SYNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEKwOFch\|ryP	NFrJUVlUSU6JRWK=
HCE-T	MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMEKwPVIh\|ryP	NFS4RlJUSU6JRWK=
NCI-H446	M1TTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7Db\|RKSzVyPUCuNFIyOTJizszN	NH\QRnZUSU6JRWK=
RPMI-6666	NETYc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mof6TWM2OD1yLkCyNVQ6KM7:TR?=	Mnv4V2FPT0WU
MOLT-16	NETnPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHQdZNKSzVyPUCuNFIyPTNizszN	NEnRbGtUSU6JRWK=
JiyoyeP-2003	NXj0Z\|A{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfyU2RCUUN3ME2wMlAzOTd4IN88US=>	M2rmVnNCVkeHUh?=
MHH-PREB-1	M1z3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmn0TWM2OD1yLkCyNVkyKM7:TR?=	MUnTRW5ITVJ?
MC-CAR	NWOwfHhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jZNGlEPTB;MD6wNlMzPiEQvF2=	Mme3V2FPT0WU
BC-3	NULCW2d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjq[odKSzVyPUCuNFI{PDRizszN	M3vVfHNCVkeHUh?=
KINGS-1	M2rjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMEKzOVUh\|ryP	M4Dmd3NCVkeHUh?=
PF-382	MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjFTWM2OD1yLkCyN\|c5KM7:TR?=	MmnFV2FPT0WU
J-RT3-T3-5	NH7DUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2X2VGlEPTB;MD6wNlM5OyEQvF2=	NHHucmtUSU6JRWK=
SF539	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwMEK0NFEh\|ryP	MnfsV2FPT0WU
LB831-BLC	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEK0PFUh\|ryP	NGrMW2hUSU6JRWK=
DMS-114	NFnPVIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;PUWVKSzVyPUCuNFI2ODJizszN	NHH3fVNUSU6JRWK=
LB1047-RCC	MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;jTWM2OD1yLkCyOVEh\|ryP	NUXTPWw2W0GQR1XS
LB771-HNC	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PSOmlEPTB;MD6wNlU{PCEQvF2=	M3G4SHNCVkeHUh?=
BB65-RCC	M1H4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEK1N\|Qh\|ryP	NGX3c2pUSU6JRWK=
BV-173	NWqyN49wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXlfYNKSzVyPUCuNFI2PTRizszN	MYjTRW5ITVJ?
ARH-77	NWjs[ZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwMEK2NFEh\|ryP	MlrEV2FPT0WU
IST-MEL1	M3vXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnhbJRPUUN3ME2wMlAzPjJ\|IN88US=>	MWjTRW5ITVJ?
NB1	NVHrRVhlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwMEK2PFch\|ryP	Mmj1V2FPT0WU
EoL-1-cell	MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrhdoRKSzVyPUCuNFI3QDhizszN	Mn7pV2FPT0WU
KY821	NF\0W21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HuemlEPTB;MD6wNlY6PyEQvF2=	NIX1NmRUSU6JRWK=
CMK	NYrHUWtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMEK3N\|Qh\|ryP	NYXlNG1bW0GQR1XS
NCI-H2126	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMEK3Olgh\|ryP	MXXTRW5ITVJ?
NCI-H526	NFTJSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwMEK4PVEh\|ryP	NYDINHN4W0GQR1XS
COLO-684	Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7MUIt1UUN3ME2wMlAzQTB6IN88US=>	NXTTXGZzW0GQR1XS
NCI-H747	MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfUTWM2OD1yLkCyPVM{KM7:TR?=	NGj6T21USU6JRWK=
JAR	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[5NpVKSzVyPUCuNFI6PDZizszN	MV7TRW5ITVJ?
MEG-01	NVHLb2VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUWzTHplUUN3ME2wMlAzQTd6IN88US=>	Mlq5V2FPT0WU
MONO-MAC-6	M4XSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIeyPW1KSzVyPUCuNFMxOjNizszN	NX\WZVZIW0GQR1XS
IST-SL1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwMEOwOFIh\|ryP	Mlr5V2FPT0WU
CPC-N	NYjGUJFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjRTWM2OD1yLkCzNFc6KM7:TR?=	NXTqSnF6W0GQR1XS
NCI-H1963	M3nBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrOZY1lUUN3ME2wMlA{OTNzIN88US=>	M1\pfXNCVkeHUh?=
K052	NHTVR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnNPXdKSzVyPUCuNFMzPDdizszN	NYXqWVJZW0GQR1XS
KM-H2	NIPQVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMEOzNFch\|ryP	NHPu[FhUSU6JRWK=
TE-12	NVTVN4RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTIZYFvUUN3ME2wMlA{OzB7IN88US=>	MWLTRW5ITVJ?
TK10	NHzObHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzOXZBKSzVyPUCuNFM{PTZizszN	M{XUWXNCVkeHUh?=
NMC-G1	Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMEO0OVIh\|ryP	Mkm2V2FPT0WU
no-11	NYrGVWxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnxTWM2OD1yLkCzOFc5KM7:TR?=	MniyV2FPT0WU
NCI-H524	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPJ[YpKSzVyPUCuNFM2OjlizszN	Mn;JV2FPT0WU
MHH-CALL-2	M2DGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMEO1OlIh\|ryP	M1fpXnNCVkeHUh?=
GB-1	Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\hZ2lEPTB;MD6wN\|Yh\|ryP	M1vafnNCVkeHUh?=
OPM-2	NHvWO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\nSpZKSzVyPUCuNFM3PzNizszN	MYPTRW5ITVJ?
RH-1	MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMEO4NVkh\|ryP	M3XobXNCVkeHUh?=
NCI-H64	NXn2Nm04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTITWM2OD1yLkCzPFU4KM7:TR?=	M1;PbXNCVkeHUh?=
EVSA-T	M1SzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzQTWM2OD1yLkCzPVI{KM7:TR?=	NF7hNFNUSU6JRWK=
KARPAS-299	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjKNmxKSzVyPUCuNFM6QCEQvF2=	NFX3TXRUSU6JRWK=
MZ7-mel	M1HCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlL3TWM2OD1yLkC0NFQh\|ryP	NV;Jb29mW0GQR1XS
LB373-MEL-D	M{TzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;yelBiUUN3ME2wMlA1OTB3IN88US=>	NUXw[\|Z2W0GQR1XS
HEL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHoTWM2OD1yLkC0NVQh\|ryP	MVvTRW5ITVJ?
SW872	NWfsVGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1X6RWlEPTB;MD6wOFIyKM7:TR?=	Mn7hV2FPT0WU
DU-4475	NEPEUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3j2SmlEPTB;MD6wOFI1PCEQvF2=	NXriXWd6W0GQR1XS
IST-SL2	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDrTWM2OD1yLkC0Nlc2KM7:TR?=	NUnGNIQ5W0GQR1XS
NCI-H82	NHjCV\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTvTWM2OD1yLkC0N\|A4KM7:TR?=	M3vHV3NCVkeHUh?=
LC4-1	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1naVmlEPTB;MD6wOFM2OSEQvF2=	Mof0V2FPT0WU
HDLM-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwMESzPVIh\|ryP	M3\QPXNCVkeHUh?=
MMAC-SF	NGfFW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O2WWlEPTB;MD6wOFU{PCEQvF2=	NHjpOJNUSU6JRWK=
L-540	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1j2OGlEPTB;MD6wOFY{QSEQvF2=	MXHTRW5ITVJ?
MZ2-MEL	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfYfHFKSzVyPUCuNFQ4PDJizszN	M2fXT3NCVkeHUh?=
LU-134-A	NVfEfpUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknyTWM2OD1yLkC0O\|c{KM7:TR?=	NGnlcI1USU6JRWK=
UACC-257	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jPe2lEPTB;MD6wOFg1QSEQvF2=	MlPoV2FPT0WU
NCI-H1581	NV;jZVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknLTWM2OD1yLkC0PVU{KM7:TR?=	NFGxRo9USU6JRWK=
NB17	MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVGwNFNHUUN3ME2wMlA1QTd7IN88US=>	NXux[lVFW0GQR1XS
SBC-1	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLOTo5JUUN3ME2wMlA2ODR{IN88US=>	M1rYTHNCVkeHUh?=
TALL-1	M33YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEWwOFUh\|ryP	M1z2[nNCVkeHUh?=
NCI-H1304	M2Oz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPxOJpkUUN3ME2wMlA2OjB6IN88US=>	NGXZOlVUSU6JRWK=
NEC8	NHfIc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT0TWM2OD1yLkC1Nlg3KM7:TR?=	MYnTRW5ITVJ?
CAL-148	M4LTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnLTWM2OD1yLkC1OFM6KM7:TR?=	NXXReYhZW0GQR1XS
CGTH-W-1	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;EN\|JrUUN3ME2wMlA2PDR7IN88US=>	NYXJT3BvW0GQR1XS
NCI-H889	NHH0[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PnTGlEPTB;MD6wOVU6OiEQvF2=	MWTTRW5ITVJ?
GR-ST	M3TLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMEW2NlEh\|ryP	M2XydHNCVkeHUh?=
KARPAS-422	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzrcIw2UUN3ME2wMlA2PjVizszN	M1jjbXNCVkeHUh?=
RPMI-8866	NFi2[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVe0OXV3UUN3ME2wMlA2PzF{IN88US=>	MoW5V2FPT0WU
SCLC-21H	M1;tN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTBwMEW4PFQh\|ryP	M33ETXNCVkeHUh?=
COR-L88	NGjkUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjFUFIyUUN3ME2wMlA2QTJ5IN88US=>	NH3te2hUSU6JRWK=
LU-139	M2HjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;QXJVnUUN3ME2wMlA2QTh4IN88US=>	MoroV2FPT0WU
SF126	M1\rNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfFVHVKSzVyPUCuNFYyOzNizszN	MX\TRW5ITVJ?
NCI-H1882	NV;PWWpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\lTWM2OD1yLkC2OFI1KM7:TR?=	NWntPZVWW0GQR1XS
EW-24	NHjicFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwME[0PFMh\|ryP	Mm\iV2FPT0WU
CP67-MEL	MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;zfmZzUUN3ME2wMlA3QDFizszN	NFjtWGRUSU6JRWK=
DG-75	NYLodoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fMS2lEPTB;MD6wOlg6QSEQvF2=	NGKzeXJUSU6JRWK=
LOXIMVI	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzOdFZKSzVyPUCuNFcxOjhizszN	MWPTRW5ITVJ?
HH	M13SSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[xN2lEPTB;MD6wO\|E2PyEQvF2=	NFqxbI1USU6JRWK=
K5	NHqzXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vXSWlEPTB;MD6wO\|IzPiEQvF2=	NHizfldUSU6JRWK=
EC-GI-10	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjkO5JLUUN3ME2wMlA4OjV5IN88US=>	MlTvV2FPT0WU
SK-N-DZ	NXvVT41pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfhWVRTUUN3ME2wMlA4OzB5IN88US=>	MVnTRW5ITVJ?
A3-KAW	NXfrcVU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEezOVEh\|ryP	MkLwV2FPT0WU
MLMA	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXL6ZYtJUUN3ME2wMlA4PDZ3IN88US=>	NH\idJRUSU6JRWK=
LB996-RCC	NX7Rb5puT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vObWlEPTB;MD6wO\|cxPyEQvF2=	MknYV2FPT0WU
OS-RC-2	MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDPO\|NKSzVyPUCuNFc4PDhizszN	NEDRdWNUSU6JRWK=
CTB-1	M3yxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTBwMEe4NUDPxE1?	MX\TRW5ITVJ?
IST-MES1	NXnC[5pnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;MXGlEPTB;MD6wO\|kyOiEQvF2=	NGTyVm1USU6JRWK=
LS-1034	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\NRpdiUUN3ME2wMlA5ODN3IN88US=>	MYrTRW5ITVJ?
HT	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIqwZWNKSzVyPUCuNFgxQDZizszN	M1;HTXNCVkeHUh?=
NCI-H2141	M4L0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PSUGlEPTB;MD6wPFEh\|ryP	NITCcoxUSU6JRWK=
LB2518-MEL	M1nidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVO4XHgyUUN3ME2wMlA5OTRzIN88US=>	MVHTRW5ITVJ?
GI-ME-N	NGC3PIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMEi0OVIh\|ryP	MnvFV2FPT0WU
TGW	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13MPGlEPTB;MD6wPFYxPyEQvF2=	MUjTRW5ITVJ?
SK-NEP-1	NHvyfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LzPGlEPTB;MD6wPFY1OSEQvF2=	Mmf6V2FPT0WU
NOMO-1	MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXYdYtbUUN3ME2wMlA6Ojd3IN88US=>	MX\TRW5ITVJ?
ES6	M1\wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEm1PFkh\|ryP	NFi2dG1USU6JRWK=
NCI-H209	NXq0N4UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3G0UWlEPTB;MD6wPVc5PiEQvF2=	NW\OcGV5W0GQR1XS
GAK	NVrYeZZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:xTWM2OD1yLkGwNVYh\|ryP	M4PZenNCVkeHUh?=
BC-1	NYi3TmNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrGTWM2OD1yLkGwN\|YyKM7:TR?=	MYnTRW5ITVJ?
KLE	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInSeIZKSzVyPUCuNVA1PDNizszN	MXTTRW5ITVJ?
EW-3	MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMUC5PEDPxE1?	NYqwWZJTW0GQR1XS
NKM-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVj2fnhoUUN3ME2wMlEyOSEQvF2=	M3PsVnNCVkeHUh?=
D-336MG	MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwMUGyOFQh\|ryP	NVXN[HM3W0GQR1XS
NB69	NWGzOGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnu3TWM2OD1yLkGxN\|AyKM7:TR?=	M3PYUnNCVkeHUh?=
D-263MG	NGHnNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlW1TWM2OD1yLkGxO\|EzKM7:TR?=	M2TTXHNCVkeHUh?=
KP-N-YS	NEfv[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwMUKyPVEh\|ryP	NGXkW5ZUSU6JRWK=
NCI-H1155	NXTu[FgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXUSnZ4UUN3ME2wMlEzPTV6IN88US=>	MlfiV2FPT0WU
BOKU	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nTeGlEPTB;MD6xNlU4QSEQvF2=	NUfLXFJnW0GQR1XS
LAMA-84	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DkUmlEPTB;MD6xNlk6KM7:TR?=	NVPxPIZuW0GQR1XS
Raji	NIDUOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jxfWlEPTB;MD6xN\|EyPyEQvF2=	MoDIV2FPT0WU
LU-65	M{LCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwMUOzNFch\|ryP	MYDTRW5ITVJ?
NCI-H187	MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrlU2ROUUN3ME2wMlE{QTJ2IN88US=>	NEnVdFNUSU6JRWK=
GCIY	NYntOW1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33Td2lEPTB;MD6xOFkxOSEQvF2=	NVTpcJNjW0GQR1XS
NCI-H2107	NG\Dd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGe0TGNKSzVyPUCuNVUxQCEQvF2=	MVvTRW5ITVJ?
NCI-H1522	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoD6TWM2OD1yLkG1NlY3KM7:TR?=	MUPTRW5ITVJ?
NB6	NWS3XWo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1H2UGlEPTB;MD6xOVYzOyEQvF2=	NHrwOYdUSU6JRWK=
EM-2	M4jCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XUVGlEPTB;MD6xOVcxPiEQvF2=	M4\SeHNCVkeHUh?=
HCC2218	NVjibXp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;lOIJKSzVyPUCuNVU6QCEQvF2=	MVPTRW5ITVJ?
NCI-H748	NGTGbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NED5ZVVKSzVyPUCuNVY{PzZizszN	MUDTRW5ITVJ?
MS-1	NIL1NGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXYemNnUUN3ME2wMlE3PTN5IN88US=>	NXrk[ow4W0GQR1XS
NB5	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwMU[1PVch\|ryP	M3zuZXNCVkeHUh?=
OMC-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXK[HNLUUN3ME2wMlE3Pjh6IN88US=>	MY\TRW5ITVJ?
NCI-H345	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV63UmxMUUN3ME2wMlE3QTJ6IN88US=>	NX[3bVhOW0GQR1XS
L-428	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\pRpBKSzVyPUCuNVY6PDVizszN	M{fNTHNCVkeHUh?=
SCH	M2S2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMUi2PFUh\|ryP	MmT4V2FPT0WU
NCI-H1417	NUmzfoYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M331WGlEPTB;MD6xPVIzPyEQvF2=	M{\mcHNCVkeHUh?=
COLO-320-HSR	NHizSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vxb2lEPTB;MD6xPVU{OiEQvF2=	NGOxT3FUSU6JRWK=
BT-474	NH7xPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwMkC4PVIh\|ryP	M3TyfXNCVkeHUh?=
GDM-1	M2rqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmC3TWM2OD1yLkKxPVcyKM7:TR?=	MVLTRW5ITVJ?
NCI-H2196	M4LFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfaU2hzUUN3ME2wMlIzOjN3IN88US=>	NHeyWopUSU6JRWK=
KP-N-RT-BM-1	NITvbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mon2TWM2OD1yLkKyN\|Q6KM7:TR?=	MVnTRW5ITVJ?
KNS-81-FD	NVLHbWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMkK5OVgh\|ryP	NEXqZYlUSU6JRWK=
COLO-668	M1LVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\SdHBjUUN3ME2wMlI{Pjd3IN88US=>	MXjTRW5ITVJ?
C2BBe1	NGD2cHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{j2RWlEPTB;MD6yOlc1PyEQvF2=	MlHKV2FPT0WU
Ramos-2G6-4C10	NGrscoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XKemlEPTB;MD6yOlk2PCEQvF2=	NHzLPWtUSU6JRWK=
CAS-1	NX3TXm9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTBwMkewPVYh\|ryP	MVjTRW5ITVJ?
GOTO	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHO5UpNKSzVyPUCuNlc5QTRizszN	NGHxT3hUSU6JRWK=
LP-1	M3Lz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvXcoNzUUN3ME2wMlI5ODV5IN88US=>	NXHyRnRjW0GQR1XS
NCI-SNU-1	NUnvT4w2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzsUYNKSzVyPUCuNlk1OjJizszN	NIDacYpUSU6JRWK=
EB-3	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3z4WmlEPTB;MD6yPVk4QSEQvF2=	NHK1cFlUSU6JRWK=
MHH-NB-11	NIT0dJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGC2NXRKSzVyPUCuN\|A1ODJizszN	NIjOZ3dUSU6JRWK=
SK-N-FI	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7pTWM2OD1yLkOxOlkzKM7:TR?=	NUfwe5prW0GQR1XS
HCC2157	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj5b2VKSzVyPUCuN\|M6OTNizszN	NEHH[XFUSU6JRWK=
SIMA	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDIV2RHUUN3ME2wMlM1PThzIN88US=>	Mo[4V2FPT0WU
MDA-MB-134-VI	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\2SIJKSzVyPUCuN\|Y6OjhizszN	MkfnV2FPT0WU
NCI-H1694	MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkmxTWM2OD1yLkO3JO69VQ>?	NH3zRXVUSU6JRWK=
EHEB	NFi3SlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zYTmlEPTB;MD6zPVA5PSEQvF2=	M4\lNHNCVkeHUh?=
U-266	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorFTWM2OD1yLkO5PFQ3KM7:TR?=	NViwZ49[W0GQR1XS
LC-1F	M3XnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPkVJJRUUN3ME2wMlQ{PzZ3IN88US=>	MoLWV2FPT0WU
SHP-77	M2fZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHz[FdKSzVyPUCuOFc5PTVizszN	M4rKW3NCVkeHUh?=
LS-513	NE\1VoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHj1OJFKSzVyPUCuOFk{ODdizszN	Mnj1V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research: ^[1]	+ Expand Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs Concentrations: 0.1-100 pM Incubation Time: 72 hours Method: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. (Only for Reference)
Animal Research: ^[5]	+ Expand Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use. Dosages: 20 mg/kg Administration: Administered via i.v. (Only for Reference)

Cell Research:

^[1]

+ Expand

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[5]

+ Expand

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

+ Expand

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Ethanol	18 mg/mL (21.07 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+5% Tween 80+ddH2O For best results, use promptly after mixing.	2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NSC 125973

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03694002	Recruiting	Locally Advanced Thymic Carcinoma\|Metastatic Thymic Carcinoma\|Recurrent Thymic Carcinoma\|Unresectable Thymic Carcinoma	Southwest Oncology Group\|National Cancer Institute (NCI)	August 9 2018	Phase 2
NCT03275818	Recruiting	Tumor Desmoplastic Small Round Cell Adult\|Tumor Desmoplastic Small Round Cell Childhood\|Sarcoma Ewing\|Sarcoma\|Desmoid	Grupo Espanol de Investigacion en Sarcomas	May 9 2017	Phase 2
NCT03057600	Active not recruiting	Triple Negative Breast Cancer\|TNBC - Triple-Negative Breast Cancer	Calithera Biosciences Inc	May 9 2017	Phase 2
NCT02775435	Active not recruiting	Non-small Cell Lung Cancer	Merck Sharp & Dohme Corp.	June 9 2016	Phase 3
NCT02181634	Completed	Cholangiocarcinoma	PrECOG LLC.\|Celgene Corporation	December 9 2014	Phase 2
NCT02415023	Completed	Gastric Cancer	Hutchison Medipharma Limited	November 9 2014	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

TAI-1 ^New

TAI-1 is a potent and specific Hec1 inhibitor, which disrupts Hec1-Nek2 protein interaction.
Docetaxel Trihydrate ^New

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Combretastatin A4 ^New

Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with K_d of 0.4 μM.Phase 3.
Docetaxel

Docetaxel, an analog of paclitaxel, is an inhibitor of depolymerisation of microtubules by binding to stabilized microtubules.
Vincristine sulfate

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Nocodazole

Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole improves the CRISPR-mediated HDR efficiency and has an additive effect on enhancing precise genome editing.
Vinorelbine Tartrate

Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
Cabazitaxel

Cabazitaxel is a semi-synthetic derivative of a natural taxoid that kills cancer cells by inhibiting cell division and growth. Cabazitaxel exerts its effects by inhibiting microtubule growth and assembly, processes that are essential for cells to divide.

Features:A semi-synthetic derivative of a natural taxoid.
Patupilone (EPO906, Epothilone B)

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC_0.01 of 1.8 μM. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 19 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel

Cited by 19 Publications

5 Customer Reviews

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Paclitaxel SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2018-10-19)

Tech Support

Frequently Asked Questions

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)